|
(Health-NewsWire.Net, July 03, 2015 ) This report provides comprehensive information on the current therapeutic developmental pipeline of Novabiotics Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Inquire more about this Report at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=393984 . (This is a premium report price at US$1500 for a single user PDF license)
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Scope:
• The report provides brief overview of Novabiotics Ltd including business description, key information and facts, and its locations and subsidiaries
• The report reviews current pipeline of Novabiotics Ltd's human therapeutic division and enlists all their major and minor projects
• The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
• Special feature on out-licensed and partnered product portfolio
• The report summarizes all the dormant and discontinued pipeline projects
• Latest company statement
Inquire for discount on this report at http://www.rnrmarketresearch.com/contacts/discount?rname=393984 . (This is a premium report price at US$1500 for a single user PDF license)
Reasons to Buy:
• Evaluate Novabiotics Ltd's strategic position with total access to detailed information on its product pipeline
• Assess the growth potential of Novabiotics Ltd in its therapy areas of focus
• Identify new drug targets and therapeutic classes in the Novabiotics Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
• Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
• Develop strategic initiatives by understanding the focus areas of Novabiotics Ltd and exploit collaboration and partnership opportunities
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Plan mergers and acquisitions effectively by identifying the most promising pipeline of Novabiotics Ltd
More reports Biotechnology Market Research Reports:
Pharmaceutical Chemicals to 2019
US demand for pharmaceutical chemicals is forecast to rise 6.1 percent annually to $54 billion in 2019. Merchant market sales primarily to generic drug companies will account for nearly one-third of this total. The remainder of demand will consist of the value of pharmaceutical chemicals produced captively or contracted for internal use by makers of proprietary drugs.
Complete report is available at http://www.rnrmarketresearch.com/pharmaceutical-chemicals-to-2019-market-report.html .
RnR Market Research
Ritesh Tiwari
+ 1 888 391 5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
